Adicet Bio, Inc. (NASDAQ:ACET) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Key Points

• Analysts have assigned Adicet Bio a consensus rating of “Moderate Buy” from eight brokers (1 sell, 1 hold, 4 buy, 2 strong buy), with an average 1‑year price target of $56.25.
• Major shareholder Ra Capital Management acquired 74,751 shares at an average $7.27, raising its stake to 1,182,624 shares; insiders bought 223,596 shares in the last 90 days and insiders own 4.6% while institutional investors hold 83.89% of the stock.
• ACET opened at $8.67 (52‑week range $6.01–$17.44) with a market cap of $83.23M; the company reported Q EPS of ($2.94), beating estimates, though analysts project about -10.26 EPS for the year.

Shares of Adicet Bio, Inc. (NASDAQ:ACET - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the eight brokerages that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, four have issued a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $56.25.

Several research analysts have recently commented on ACET shares. Guggenheim lowered their price target on Adicet Bio from $128.00 to $100.00 and set a "buy" rating for the company in a research report on Friday, March 13th. HC Wainwright reduced their price objective on Adicet Bio from $50.00 to $27.00 and set a "buy" rating on the stock in a research note on Monday, March 23rd. Truist Financial upgraded Adicet Bio to a "strong-buy" rating in a research note on Wednesday, March 25th. Weiss Ratings reiterated a "sell (d-)" rating on shares of Adicet Bio in a research note on Tuesday, January 27th. Finally, Canaccord Genuity Group set a $18.00 price objective on Adicet Bio and gave the company a "buy" rating in a research note on Tuesday, January 6th.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. acquired 74,751 shares of Adicet Bio stock in a transaction dated Friday, February 20th. The shares were acquired at an average cost of $7.27 per share, for a total transaction of $543,439.77. Following the completion of the purchase, the insider owned 1,182,624 shares in the company, valued at approximately $8,597,676.48. The trade was a 6.75% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders acquired 223,596 shares of company stock valued at $1,603,934 in the last 90 days. 4.60% of the stock is currently owned by company insiders.

Institutional Trading of Adicet Bio

Hedge funds have recently modified their holdings of the stock. Susquehanna International Group LLP acquired a new stake in shares of Adicet Bio in the third quarter valued at $33,000. Squarepoint Ops LLC acquired a new stake in Adicet Bio in the third quarter valued at $38,000. Virtu Financial LLC acquired a new stake in Adicet Bio in the third quarter valued at $65,000. Citadel Advisors LLC raised its stake in Adicet Bio by 19.8% in the third quarter. Citadel Advisors LLC now owns 583,948 shares of the company's stock valued at $473,000 after buying an additional 96,342 shares in the last quarter. Finally, Two Sigma Investments LP raised its stake in Adicet Bio by 66.6% in the third quarter. Two Sigma Investments LP now owns 854,568 shares of the company's stock valued at $692,000 after buying an additional 341,761 shares in the last quarter. 83.89% of the stock is currently owned by institutional investors and hedge funds.

Adicet Bio Stock Up 5.5%

ACET opened at $8.67 on Tuesday. Adicet Bio has a 52 week low of $6.01 and a 52 week high of $17.44. The business has a fifty day simple moving average of $7.10 and a 200-day simple moving average of $9.01. The firm has a market cap of $83.23 million, a P/E ratio of -0.48 and a beta of 1.57.

Adicet Bio (NASDAQ:ACET - Get Free Report) last released its quarterly earnings results on Thursday, March 12th. The company reported ($2.94) EPS for the quarter, topping the consensus estimate of ($3.23) by $0.29. Sell-side analysts expect that Adicet Bio will post -10.26 earnings per share for the current year.

About Adicet Bio

Adicet Bio, Inc NASDAQ: ACET is a clinical‐stage biotechnology company specializing in the development of off‐the‐shelf, allogeneic gamma delta (γδ) T cell therapies for oncology and autoimmune disorders. The company's proprietary platform enables the genetic engineering of γδ T cells with chimeric antigen receptors (CARs) and other molecular modifications to enhance tumor targeting, expansion, and persistence. By leveraging the innate tumor-recognition properties of γδ T cells, Adicet seeks to overcome the manufacturing and safety challenges associated with autologous cell therapies.

Adicet's lead product candidate, ADI-001, is a CAR‐engineered allogeneic γδ T cell therapy directed against CD20 for the treatment of relapsed or refractory B-cell malignancies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.